Darifenacin

Also Known As: Darifenacin, Enablex, Emselex

Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medicationused to treat urinary incontinence. It used to be marketed by Novartis; however in 2010 US rights for were sold to Warner Chilcott for 400 million US$.

Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

It should not be used in people with urinary retention. Anticholinergic agents, such as Enablex, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as Enablex are used in a hot environment. [1]

Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults.

 
Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:
  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Darifenacin to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.